BGMD.US BG Medicine Inc
- Market cap
- USD 1.14K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 219,876.87%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2022.
Is BGMD.US undervalued?
Graham numberThe Graham number of BG Medicine Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BG Medicine Inc fundamental analysis
No fundamental analysis for BG Medicine Inc yet.
BG Medicine Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BG Medicine Inc
BG Medicine, Inc., a diagnostics company, engages in the development and commercialization of novel cardiovascular diagnostic tests to address unmet medical needs in the United States, Europe, and internationally. It offers BGM Galectin-3 test, a novel diagnostic test that measures galectin-3 in blood plasma or serum; and CardioSCORE test that is designed to identify cardiovascular events, such as heart attack and stroke. The company was formerly known as Beyond Genomics, In…
Full company profileBG Medicine Inc financial statements
BG Medicine Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 819K | 1.63M | 2.82M | 4.07M | 2.79M | 1.57M | - | - | - | - |
| Gross Profit | 33.0K | 1.02M | 1.86M | 2.68M | 1.83M | 1.06M | - | - | - | - |
| Operating Income | -14.6M | -17.5M | -22.7M | -14.4M | -7.36M | -4.63M | - | - | - | - |
| EBITDA | -13.8M | -17.1M | -22.4M | -14.8M | -7.21M | -5.06M | - | - | - | - |
| Net Income | -17.2M | -17.6M | -23.8M | -15.8M | -8.06M | -5.30M | - | - | - | - |
| EPS | -23 | -3.99 | -4.70 | -2.33 | -0.99 | -0.55 | - | - | - | - |
| Balance Sheet | ||||||||||
| Total Assets | 7.03M | 26.1M | 15.2M | 9.35M | 5.23M | 2.13M | - | - | - | - |
| Total Liabilities | 84.4M | 5.22M | 14.9M | 10.4M | 4.67M | 4.11M | - | - | - | - |
| Shareholders' Equity | -77.4M | 20.9M | 309K | -1.07M | 557K | -1.98M | - | - | - | - |
| Cash & Short-term Investments | 2.43M | 23.9M | 12.8M | 7.75M | 4.12M | 1.53M | - | - | - | - |
| Total Debt | 96.0K | - | 9.86M | 7.31M | 2.96M | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -11.4M | -15.0M | -21.3M | -15.3M | -8.17M | -3.67M | - | - | - | - |
| Capital Expenditure | 77.0K | 93.0K | 85.0K | 132K | 0.00 | 0.00 | - | - | - | - |
| Free Cash Flow | -11.5M | -15.1M | -21.4M | -15.4M | -8.17M | -3.67M | - | - | - | - |
| Ratios | ||||||||||
| ROE | - | -84.2% | -7,692.2% | - | -1,447.8% | - | - | - | - | - |
| ROA | -244.2% | -67.3% | -156.0% | -169.5% | -154.2% | -248.6% | - | - | - | - |
| Net Profit Margin | -2,095.5% | -1,076.0% | -844.4% | -389.1% | -289.3% | -338.6% | - | - | - | - |
| Debt to Equity | - | - | 31.90x | - | 5.31x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BG Medicine Inc dividends
- Dividend yield
- 219,876.87%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2015 | USD 2.50M | 0.26 | - |
| 2014 | - | - | - |
| 2013 | - | - | - |
| 2012 | - | - | - |
| 2011 | - | - | - |
| 2010 | - | - | - |
| 2009 | - | - | - |
| 2008 | - | - | - |
| 2006 | - | - | - |
| 2005 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:4 on Jul 9, 2015.
Who owns BG Medicine Inc
Ownership data of BG Medicine Inc is not available yet.
BG Medicine Inc company profile
- Company name
- BG Medicine Inc
- Ticker
- BGMD.US
- Exchange
- USA Stocks
- Listed since
- Feb 4, 2011
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 5
- Fiscal year end
- December
- Address
- 303 Wyman Street, Waltham, MA, United States, 02451
- Phone
- 781 890 1199
- Website
- bg-medicine.com
About BG Medicine Inc
BG Medicine, Inc., a diagnostics company, engages in the development and commercialization of novel cardiovascular diagnostic tests to address unmet medical needs in the United States, Europe, and internationally. It offers BGM Galectin-3 test, a novel diagnostic test that measures galectin-3 in blood plasma or serum; and CardioSCORE test that is designed to identify cardiovascular events, such as heart attack and stroke. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was incorporated in 2000 and is headquartered in Waltham, Massachusetts.
BG Medicine Inc management
1- Mr. Stephen P. HallCFO, Executive VP & Treasurer · born 1951